A single high dose of psilocybin causes likely anatomical changes in the human brain that persist for up to 30 days after the initial psychedelic experience. Researchers at UC San Francisco (UCSF) and Imperial College London have demonstrated that these physical shifts correlate directly with psychological insight and long-term improvements in mental well-being.
The study, published in Nature Communications, utilised a cohort of 28 healthy volunteers who had no prior experience with psychedelics. By monitoring subjects who were not diagnosed with mental health conditions, scientists were able to conduct a rigorous assortment of brain imaging and measurement techniques before, during, and after the experience to map the drug’s enduring impact on neural architecture.
“Psychedelic means ‘psyche-revealing,’ or making the psyche visible,” said senior author Robin Carhart-Harris, PhD, the Ralph Metzner Distinguished Professor of Neurology at UCSF. “Our data shows that such experiences of psychological insight relate to an entropic quality of brain activity and how both are involved in causing subsequent improvements in mental health”.
Measuring the ‘trip’
The experiment was structured to compare a 1 mg placebo dose against a 25 mg therapeutic dose. Within 60 minutes of taking the higher dose, electroencephalography (EEG) recordings revealed a significant increase in “entropy”—a measure of the diversity and richness of neural activity occurring in the brain.
The degree of entropy measured during the acute “trip” served as a predictor for the level of emotional self-awareness, or insight, that volunteers reported the following day. Crucially, this reported insight forecasted measurable improvements in optimism and problem-solving abilities one month later.
Anatomical density and cognitive flexibility
One month after the 25 mg dose, researchers used diffusion tensor imaging (DTI) to measure the diffusion of water along neural tracts. They discovered that these tracts had become denser and exhibited greater structural integrity. This finding is particularly significant as it represents the inverse of the natural neural diffusion that typically occurs during the human ageing process.
Beyond physical density, the participants demonstrated enhanced cognitive flexibility during testing four weeks post-study. The volunteers reported higher well-being scores, responding positively to indicators such as dealing with problems effectively and feeling optimistic about the future.
“Psilocybin seems to loosen up stereotyped patterns of brain activity and give people the ability to revise entrenched patterns of thought,” said first author Taylor Lyons, PhD, a research associate at Imperial College London. “The fact that these changes track with insight and improved well-being is especially exciting”.
Implications for psychedelic therapy
The researchers concluded that the psychedelic experience itself — rather than just the compound’s chemical interaction — is vital to long-term therapeutic outcomes. The study suggests that improved mental health is driven by the experience of insight, which is in turn sparked by increased entropic brain activity.
These results provide a mechanical explanation for how psilocybin might treat conditions such as anxiety, depression, and addiction. By understanding the relationship between dosage, entropy, and insight, clinicians may be able to better calibrate treatments to ensure subjects achieve the necessary neural shifts to promote lasting psychological recovery.
“We already knew psilocybin could be helpful for treating mental illness,” Carhart-Harris noted. “But now we have a much better understanding of how”.
